1.Clinical analysis of 57 cases of thyroid disease with concomitant focal lymphocytic thyroiditis
Zhendong LEI ; Gannong CHEN ; Mingxing WEN ; Enxiang ZHOU ; Yunshan LI
Chinese Journal of General Surgery 2001;0(09):-
Objective To evaluate the methods of diagnosis and treatment of thyroid disease with concomitant focal lymphocytic thyroiditis(FLT), and explore the reasons for its confused with Hashimoto′s disease(HD).Methods During the recent 25 years, 207 patients underwent surgical trearment for pathologically diagnosed HD.Among this group, 143 cases of HD with other concomitant thyroid disease were retrospectively analysed.Results Of the 143 cases, 57 cases were found to have thyroid disease with concomitant FLT, and this was 27.5%(57/207) of the total HD group, or 39.9%(57/143) of the group with thyroid disease and concomitant HD.Intraoperative pathologic section revealed that focal lymphocytic infiltration was positive in 87.7%(50/57) of cases. The postoperative hypothyroidism occurrence rate was 19.3%(11/57), of which, 7 cases(7/57, 12.3%) were subclinical hypothyroidism.Conclusions The character of pathologic changes of thyroid disease with FLT and with HD was different. Intraoperative pathologic section can be helpful in the diagnosis of this condition and can have important significance as a guide to the scope of (surgical) resection of the thyroid gland.
2.Primary and metastatic hepatic neuroendocrine carcinoma: a clinicopathological study
Wenshu ZHANG ; Jing ZHAO ; Yuan JI ; Bo YANG ; Lingli CHEN ; Yunshan TAN ; Akesu SUJIE ; Xiongzeng ZHU
Chinese Journal of Hepatobiliary Surgery 2012;18(3):161-165
Objective To study the clinicopathological features of primary and metastatic hepatic neuroendocrine carcinoma.Methods The records of 35 patients with primary hepatic neuroendocrine carcinoma and 35 patients with metastatic hepatic neuroendocrine carcinoma were retrospectively reviewed.These patients served as the primary group(priNET,n=35)and the metastasis group (metNET,n=35),respectively.Results There were significant differences between the two groups of patients in gender,site,size and number of tumor(P<0.05).Although there was no significant difference between the two groups in the distribution of the tumors in the two lobes of liver (P>0.05),priNET had more tumors localized to one lobe of liver while metNET had more tumors involving both lobes of liver(P<0.05).Conclusions Gender,size,site and number of tumor may play an important role in the differentiation of primary or metastatic hepatic neuroendocrine tumor.
3.Value of ultrasonic scoring system for predicting risks of placenta accreta
Yiwen CHONG ; Aiqing ZHANG ; Yan WANG ; Zhaohui LIU ; Yunshan CHEN ; Yangyu ZHAO
Chinese Journal of Perinatal Medicine 2016;19(9):705-709
Objective To explore the value of ultrasound scoring system in predicting the type and risk of placenta accreta.Methods Clinical data of 180 placenta accreta patients who delivered in the Peking University Third Hospital between January 2005 and November 2014,were retrospectively analyzed.Prenatal ultrasonographic features were analyzed,including position and thickness of the placenta,disappearance of hypoechoes in posterior placenta,continuousness of bladder line,existence of lacuna,condition of the subplacental vascularity,completeness of cervical morphology,existence of cervical sinus,and history of cesarean section.A score of 0,1 or 2 was given to each item,and a sum-up was calculated for each patient.The cut-off scores of patients with placenta accreta,placenta increta and placenta percreta were calculated by receiver operating characteristic carve,respectively.At the same time,blood loss and hysterectomy rate were compared among the three groups.Variance analysis,rank sum or Chi-square tests were used for statistical analysis.Results Among the 180 cases,there were 115 cases of placenta accreta,38 of planceta increta and 27 of placenta percreta.Placenta increta and percreta were defined as the severe type.Blood loss in placenta accreta was lower than in the severe type [200 (100-4 000) ml vs 3 025 (100-15 000) ml,P<0.01].There was no difference in blood loss between patients with placenta increta or percreta (P=0.350).No hysterectomy was performed for patients with placenta accreta,the rate being lower than in the severe type [0 vs 29.2% (19/65),P<0.01].Among the severe type,18.4% (7/38) of the placenta increta patients underwent hysterectomy,the rate being lower than in placenta percreta patients [44.4% (12/27),P<0.01].The score in placenta accreta was lower than in the severe type [(1.88± 1.45) vs (7.01 ±2.15) scores,P<0.01].In the severe type,the score in placenta increta was lower than in placenta percreta [(6.08 ± 2.62) vs (8.74 ± 2.75),P<0.01].The receiver operating characteristic curve showed that the cut-off score of placenta accreta and the severe type was 5 [area under the curve (AUC)=94.3%,the score ≥ 4.5,the sensitivity=81.5%,and the specificity=95.7%],the cut-off score of placenta accreta and increta was 3 (AUC=91.1%,score ≥ 2.5,the sensitivity=92.1%,and the specificity=75.7%),and the cut-off score of placenta increta and percreta was 10 (AUC=74.6%,score ≥ 9.5,the sensitivity=55.6%,and the specificity=89.5%).Conclusions Ultrasound scoring system is effective in assessing types of placenta accreta and predicting its associate risks,and alerting the possibility of hysterectomy.It also facilitates preoperative planning and guides physicians in formulating subsequent treatment plans.Placenta accreta and the severe type (placenta increta and percreta) can be distinguished by cut-offscores ≥ 5,and a score ≥ 10 implies a higher risk of placenta percreta.
4.A study on the expression of erbB4/HER4 and VEGF in NSCLC
Zaichun DENG ; Yiming YU ; Gun CHEN ; Guoping ZHONG ; Yunshan TAN ; Yonghua XU ; Chunxue BAI
Journal of Chinese Physician 2008;10(4):475-477
Objectives To explore the expression of HER4 and VEGF in NSCLC and elucidate the relationship between their expression and the characteristic of clinical pathology. Methods 82 cases of paraffin-embedded tissues from informative NSCLC were used to detect the expression of HER4 and VEGF by means of immunohistochemical assay. Results HER4 is overexpressed in 65;9%of NSCLC cases. The overexpression of HER4 is correlated with the lymph node metastasis and TNM staging. VEGF is expressed in 53.7%of NSCLC cases. The expression of VEGF is also correlated with the lymph node metastasis and TNM staging, and the expression of VEGF is correlated with the overexpression of HER4.Conclusions HER4 and VEGF are the protein to regulate the growth of NSCLC and it might be a good way for the treatment of NSCLC by suppressing the overexpression of HER4 and VEGF.
5.Expression of connective tissue growth factor induced by parathyroid hormone via MAPK signaling pathway in human renal proximal tubular cells
Yunshan GUO ; Weijie YUAN ; Xiaoli ZHAN ; Ling LIU ; Ying ZHANG ; Wei CHEN ; Hanyang YE
Chinese Journal of Nephrology 2008;24(6):423-428
Objective To evaluate the effect of parathyroid hormone (PTH) on the expression of connective tissue growth factor (CTGF) in human renal tubular epithelial cells, and to explore the role of MAPK signaling pathway. Methods Real time RT-PCR, Western blot, and reporter gene assay were employed to detect PTH-induced CTGF expression in HK-2 cells. Inhibitors (PD98059 and U0126) of MAPK signaling pathway were used to confirm involved signal pathway. Results HK-2 cells had basic expression level of CTGF mRNA and protein, which were increased significantly after treatment with PTH. The luciferase activity was up-regulated to a higher level as compared with control group after treatment with 10-10 mol/L PTH for 12 h [(1.8884±0.0780) vs (0.9891±0.0300) A, P<0.01]. Moreover, a small amount of p-ERK1/2 was detected in normal HK-2 cells, but it was increased significantly in response to PTH activation, most remarkably when treated with 10-10 mol/L PTH for 30 min. Inhibitors of MAPK signaling pathway, PD98059 and U0126, noticeably inhibited the expression of CTGF mRNA and protein as well as gene promoters in HK-2 cells. Conclusion PTH can induce higher expression of CTGF in HK-2 cells probably via MAPK signaling pathway.
6.Enhanced antitumor effects of exosomes derived from heat-shocked E.G7-OVA tumor cells
Haijun ZHONG ; Yunshan YANG ; Shenglin MA ; Weimin MAO ; Yiping ZHANG ; Fangming XIU ; Zhijian CAI ; Weilin CHEN ; Qingqing WANG
Chinese Journal of Microbiology and Immunology 2010;30(2):164-168
Objective To study the antitumor effects of exosomes derived from heat-shocked E.G7-OVA tumor cells in vivo. Methods Exosomes derived from E.G7-OVA tumor cells were isolated and purified by serial centrifugation and sucrose gradients ultracentrifugation. Exosomes from heat-shocked or non-heat-shocked E.G7-OVA tumor cells were named as Exo/HS and Exo correspondingly. Exosomes were viewed by electron microscopy. Protein components of exosomes were detected by Western blot. Exo, Exo/ HS or PBS were injected into mice before injection of E.G7-OVA tumor cells, and antitumor effects were ob-served in each group. Mouse model bearing E.G7-OVA tumor cells were established to examine immunother-apy effects of Exo or Exo/HS. Cytotoxity of spleen CTL were measured by LDH. Results Exosomes con-tained bi-layer membrane and their diameters are between 40 nm and 100 nm under electron microscopy. The Western blot results showed that HSC70, HSP70, HSP60, HSP90, MHC Ⅰ and OVA were present in both Exo and Exo/HS. However, Exo/HS contained more HSP70 and MHC Ⅰ than Exo. Protective antitu-mor immunity suggested that tumor-free survival (90 days) rate in Exo/HS vaccinated mice was significantly higher than those in Exo or PBS vaccinated mice (50%, 20%, 0%, P<0.01). Therapeutic antitumor effects showed that immunization by Exo/HS resulted in dramatically enhanced antitumor effects when com-pared to the Exo- or PBS-treated groups (P<0.01). CTL results showed that immunization with Exo/HS in-duced higher level of OVA-specific CTL responses as compared with those from Exo or PBS (P<0.01). Conclusion Exosomes derived heat-shocked E.G7-OVA tumor cells may be used as potent cancer vaccine.
7. Application of cervical lifting suture in hemostasis of placenta previa with increta and percreta
Yunshan CHEN ; Yangyu ZHAO ; Yan ZHANG ; Yan WANG ; Yiwen ZHONG ; Aiqing ZHANG
Chinese Journal of Obstetrics and Gynecology 2018;53(7):459-463
Objective:
To evaluate the effect of cervical lifting suture in treatment of placenta previa with increta and percreta.
Methods:
From January 2016 to June 2017, 65 cases (0.78%, 65/8 322) were diagnosed placenta previa with increta and percreta by prenatal ultrasonic score system and confirmed by intraoperative findings in the department of obstetrics and gynecology of Peking University Third Hospital. Totally 62 cases (0.75%, 62/8 322) were included, because 3 cases underwent hysterectomy with placenta in situ. According to ultrasonic score system, 62 cases were divided into two groups, score 5-9 group (
8.Genotype and phenotype studies on fetuses of 22q11.2 deletion syndrome.
Haiyan ZHU ; Yunshan ZHANG ; Chunyan JI ; Shanshan LI ; Yanyan NIU ; Hairong ZHANG ; Lei CHEN
Chinese Journal of Medical Genetics 2020;37(7):721-724
OBJECTIVE:
To study the genotype and phenotype of fetuses with 22q11.2 microdeletion and other abnormalities such as cardiac malformation and cleft palate.
METHODS:
Fetal ultrasound was carried out at 12 weeks to 20 to 24 weeks of gestation. After excluding the chromosomal karyotype abnormality, single nucleotide polymorphism (SNP) array was used to detect copy number variations of 5 fetuses with heart development abnormality or other structural abnormalities. The fetus with 22q11.2 microdeletion and its parents were also subjected to multiplex ligation-dependent probe amplification (MLPA) assay.
RESULTS:
SNP array analysis showed that the 5 fetuses had all carried a 2.27-3.02 Mb deletion of the 22q11.2 region. MLPA assay confirmed that LCR22-A-B was involved in all cases, and that all deletions were de novo in origin.
CONCLUSION
It is of great significance to exclude 22q11.2 microdeletions in fetuses with cardiac malformations. The deletion regions of these fetuses are similar but different, and the phenotypic difference is related to their genotypes.
9.Inhaled nitric oxide as a salvage therapy for refractory hypoxemia in the post-transplantation period of hepatopulmonary syndrome:An explorative report of three cases
Lyu HAIJIN ; Yi XIAOMENG ; Zou YUNSHAN ; Lu PINGLAN ; Li LIJUAN ; Liu JIANRONG ; Chen SENBIAO ; Wei XUXIA ; Yang YANG ; Yi HUIMIN
Liver Research 2024;8(3):188-192
Liver transplantation(LT)is the only effective treatment for hepatopulmonary syndrome(HPS).Moreover,perioperative refractory hypoxemia(pRH)is a prevalent life-threatening condition and has extremely limited treatment options.Here,we report three patients with HPS who experienced pRH after LT and were consecutively treated with different salvage therapies,ephedrine inhalation,intravenous use of methylene blue with nitric oxide(NO)inhalation,and NO inhalation alone.The results showed that unresolved severe hypoxia may induce fatal morbidity such as early biliary leakage and acute kidney injury.Early initiation of NO inhalation,rather than ephedrine,can significantly improve oxygenation in patients with pRH and may help prevent hypoxia-related complications.Therefore,based on the response to these exploratory salvage treatments,we further demonstrate the unique ventilation-perfusion mismatch pathophysiology in specific lung regions during pRH in HPS.We propose that early inhalation of NO is an important treatment option to rescue severe hypoxia in patients with HPS during the perioperative period of LT.
10.Dysplastic nodule of liver versus early hepatocellular carcinoma:a clinicopathologic and prognostic study
Lingli CHEN ; Yunshan TAN ; Haiying ZENG ; Yingyong HOU ; Jianfang XU ; Jing ZHAO ; Yuan JI
Chinese Journal of Pathology 2014;(5):301-306
Objective To study the clinical features , pathologic findings and prognosis of patients with dysplastic nodules of liver ( DN ) and early hepatocellular carcinomas ( eHCC ).Methods One hundred and forty-five archival cases previously diagnosed as DN or eHCC or well-differentiated HCC during the period from 2000 to 2009 were retrieved and reevaluated with the new diagnostic criteria by two experienced pathologists , according to International Consensus Group for Hepatocellular Neoplasia ( ICGHN) 2008.Immunohistochemical study (EnVision method) for CD34, HSP70, glutamine synthetase, glypican 3 and Ki-67 was carried out.The original diagnosis and diagnosis after review were compared and correlated with the survival data of the patients , with statistical analysis.Results With the new criteria , 16 cases were diagnosed as low-grade DN, 50 cases as high-grade DN, 72 cases as DN with microinvasion , 7 cases as advanced HCC.Slide review showed no diagnostic discrepancy in 112 cases ( 77.2%).Amongst the 33 (22.8%) underdiagnosed cases , there were 7 cases of advanced HCC initially diagnosed as DN or DN with microinvasion and 26 cases of eHCC initially diagnosed as high-grade DN.Kaplan-Meier analysis showed that the diagnosis of high-grade DN or early HCC carried no statistically significant difference in overall survival (P=0.778, 0.677) or disease-free survival (P=0.949, 0.700) in all patients and in patients with no history of HCC.The co-existence of advanced HCC in patients with DN or eHCC significantly correlated with overall survival (P=0.004) but not with disease-free survival (P=0.079).Conclusions The new diagnostic criteria by ICGHN 2008 are useful in delineating high-grade DN and eHCC.The overall survival and disease-free survival of patients with eHCC or high-grade DN undergoing hepatectomy show no statistically significant difference.Patients with DN or eHCC have better prognosis than patients with advanced HCC , though there is still a high risk of tumor recurrence .